Retatrutide dosage figures in circulation are trial arms, not doses. They come from a Phase 2 study published in the New England Journal of Medicine in 2023 by Jastreboff and colleagues, where the highest arm, 12 mg, produced roughly 24 percent mean weight reduction at 48 weeks in adults with obesity.
The vendor we point lifters to
Retatrutide from Ascension Peptides
Independently assayed material, dispatched from the US. Both vial sizes drop by half with the code below.
The certificate that resolves for this compound is MZ Biolabs lot 03-01260229, reporting 99.94 percent purity and 11.67 mg against a 10 mg label, purity and quantity only, with no endotoxin or sterility screen. A second certificate is linked on the product page and does not load. Buying 3, 5 or 10 takes 3%, 5% or 10% off the list price. Free shipping starts at $250.
- One resolving lab report per batch
- Free delivery above $250
- Same-day dispatch on orders before 2pm CST
Research material, laboratory use only, not for human consumption. Affiliate links: we may earn a commission at no extra cost to you. Pricing verified September 9, 2026.
That result is real, it is in humans, and it is unusual for anything covered on this site. Most compounds a lifter finds through the same channels have a rodent literature and a sales page. This one has a large randomised trial and a headline number that got through peer review at a serious journal.
It also has no approval anywhere on earth. No regulator has licensed it, no pharmacy dispenses it, and there is no label to read. What circulates instead are trial arms lifted out of a supervised study and repeated as though they were instructions.
For a reader who tracks lean mass rather than scale weight, the gap between those two things matters more than usual, because dose and body composition cost move in the same direction.
The figure is a trial arm, and a trial arm is not a label
A trial dose exists inside a structure. Participants were screened for eligibility, randomised, escalated under supervision, monitored on a schedule, and free to stop. Adverse events were recorded by people whose job was to record them. The amount was one variable inside a design built to answer a question about a group, not advice issued to a person.
A label is the other end of that process. It arrives after regulatory review and carries an indication, a population, contraindications, interactions and a monitoring expectation. Retatrutide has the first thing and none of the second. The Phase 3 programme, TRIUMPH, is still running.
So when a forum post quotes a number, the number may well be accurate as a description of what the trial did. It is still not a dose in the sense the reader wants, because the thing that converts a tested amount into a usable one has not happened.
Retatrutide dosage is a trade, not a target
Here is the part that weight loss coverage tends to leave out.
Across this drug class the relationship between dose and weight lost is fairly orderly in humans. More receptor agonism produces more appetite suppression, which produces a larger and more sustained energy deficit, which produces more weight off. The relationship between dose and lean tissue runs in the same direction, for the same reason. A bigger deficit held for longer takes more of everything, and some of what it takes is tissue that took years to build.
The largest arm is therefore not simply the best arm. It is the arm with the biggest number in both columns. A lifter at forty two, whose body already rebuilds muscle more slowly than it did at twenty five, is not choosing whether to lose lean mass. They are choosing how much.
| Claim attached to a dose figure | What supports it | Organism |
|---|---|---|
| The top arm produced roughly 24 percent mean weight reduction at 48 weeks | The published Phase 2 trial | Human |
| Effects were dose related, including the unwanted ones | The same trial's adverse event reporting | Human |
| A larger amount preserves muscle better | Nothing | None |
| Any amount is safe outside a monitored trial | Nothing, there is no approval in any market | None |
| Everything lost is fat | Body composition substudies of related incretin drugs report a meaningful share as fat free mass | Human |
Read the third row against the fifth. That is the entire body composition argument, in two lines.
What comes off the body along with the fat
Fat free mass is not a synonym for muscle. It includes water, glycogen and the water bound to it, gut contents, and organ tissue. Early in a steep deficit a large part of the fat free number is glycogen and fluid, and that portion returns the moment eating normalises. Anyone quoting a fat free mass figure as though it were pure muscle is overstating the damage.
The honest version is narrower and still uncomfortable. Over a long deficit, with a large total loss, some of the fat free mass that leaves is contractile tissue, and it does not come back on its own. In an older lifter it comes back slowly even with deliberate work, because the anabolic response to both training and protein is blunted with age in humans.
Retatrutide's distinguishing feature is the size of the total loss. The proportion may or may not turn out to be worse than older agents in this class. The absolute quantity of tissue moving is larger simply because more mass is moving.
Three receptors, and why the third one matters here
Retatrutide is described as a triple agonist: it acts at the GIP, GLP-1 and glucagon receptors. The first two are familiar from approved obesity drugs and drive the appetite side of the effect. The third is the addition, and it is the reason the dose conversation is different.
Glucagon receptor agonism pushes on energy expenditure and on hepatic fuel handling rather than on appetite. In principle that means part of the deficit is produced by output rather than by intake alone, which is a genuinely different lever from the one older agents pull.
Whether that changes the composition of the weight lost is exactly the question nobody has answered. A deficit created partly by raising expenditure is still a deficit, and the body meets a deficit by drawing on whatever is available. There is no published result in humans showing that the glucagon component spares lean tissue, and it would be a mistake to assume a novel mechanism must be a protective one.
The two defences that human trials actually support
Two interventions have repeated human evidence behind them for holding lean tissue during weight loss, and neither of them is a peptide.
The first is resistance training maintained through the deficit. Trials in dieting humans have consistently reported that lifting during weight loss preserves more lean mass than dieting alone. That work was done in people losing weight by eating less, not in people on an incretin drug, and nobody has run the combination as a trial with retatrutide.
The second is protein intake held toward the upper end of what the sports nutrition literature recommends rather than the general population figure. Again, human evidence, again in conventional dieters.
The collision is obvious once stated. The mechanism producing the weight loss is appetite suppression, and a suppressed appetite makes a high protein intake harder to reach, not easier. The drug works by making eating less attractive, and the countermeasure requires eating something specific reliably. Nobody has published a trial resolving that tension for this compound.
What no milligram figure can tell you
It cannot tell you your own response. Trials report group means, and the spread around a mean in this drug class is wide in humans.
It cannot tell you what is in an unregulated vial. There is no pharmacopoeial standard for a product no regulator has approved, so identity, purity and concentration are unverified by anyone.
It cannot tell you your own split between fat and fat free mass, which requires repeated body composition measurement rather than a scale.
And it cannot tell you what happens after. Discontinuation in this class has been followed by weight regain in humans, and whether the regained mass returns in the same proportions it left is a live question rather than a settled finding.
Questions readers bring to the dose numbers
Is there an approved amount of retatrutide to take?
No. The compound is unapproved in every market. There is no licensed indication, no dispensing route, and therefore no approved amount anywhere.
Does a dose used in a trial mean that amount is safe?
It means it was administered under monitoring to a screened population with defined exclusions, and that adverse events were recorded. Safety in that setting is a statement about a supervised group, not a guarantee transferable to an unscreened individual buying from a grey market.
Would a smaller amount protect lean mass?
A smaller deficit generally costs less lean tissue in humans, and dose drives the deficit here. That reasoning is coherent, but no trial of this compound has tested lean mass preservation as an outcome across arms, so it remains an inference rather than a result.
Did the published trial report body composition?
The headline outcome was weight reduction. Detailed muscle specific outcomes are not something a reader should assume from a weight endpoint, and the class level body composition data come from studies of other drugs in the family.
Does the appetite effect make protein targets harder to reach?
That is the practical problem people report on incretin drugs generally. Reduced intake is the mechanism of action, and it does not selectively spare the protein portion of a meal.
Is any of this a recommendation?
No. Every figure here describes what a trial administered under supervision. Nothing on this page is a protocol, and no unapproved compound has one.